An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty

Trial Profile

An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Precocious puberty
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 11 Apr 2017 Planned End Date changed from 1 Mar 2018 to 31 Dec 2018.
    • 11 Apr 2017 Planned primary completion date changed from 1 Mar 2018 to 31 Dec 2018.
    • 11 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top